Blocking a kidney protein accelerates recovery after injury

UCLA researchers have demonstrated that inhibiting the ENPP1 protein in kidney tissue significantly accelerates recovery following injury, reducing scar formation and improving organ function. When a kidney sustains damage, it produces ENPP1, a protein that triggers a metabolic cascade disrupting cellular energy production and impairing tissue repair. In murine models exposed to nephrotoxic diets and damaging agents, mice unable to produce ENPP1 showed markedly reduced serum creatinine, BUN, and cystatin C levels—hallmarks of renal dysfunction—after four weeks, while controls maintained elevated levels. The drug AD-NP1, a monoclonal antibody already approved for phase 1 human clinical trials, was engineered specifically to neutralize ENPP1 without affecting other proteins. Although the technique was initially developed for cardiac regeneration post-infarction, these findings suggest broader applications in aged tissue maintenance, though effects in organs without acute injury will require additional validation.